Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) reduce elevated blood glucose
levels and induce weight loss. Multiple GLP‐1 RAs and one combined GLP‐1/glucose …

Introduction Once-weekly semaglutide is a glucagon-like peptide-1 (GLP-1) analogue that is
currently available as 1.0 mg and 0.5 mg dose for the treatment of type 2 diabetes (T2D) …

Objective: Semaglutide is a glucagon-like peptide 1 (GLP-1) analog for the once-weekly
treatment of type 2 diabetes (T2D). In the global SUSTAIN clinical trial program, semaglutide …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used to address multiple
aspects of type 2 diabetes mellitus (T2DM) management, including glycaemic control …

Background There are currently limited data regarding the effect of semaglutide 2· 4 mg in
individuals with obesity and prediabetes in clinical trials. We aimed to assess the efficacy …

Semaglutide is a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) with a long
elimination half‐life, allowing subcutaneous (sc) administration once per week. Both the …

Background The weight loss benefit of semaglutide in patients with diabetes is well-
documented, but its clinical utility in treating obesity among patients without diabetes is less …

Introduction The relative efficacy and safety of once-daily oral semaglutide vs. injectable
glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in subjects with type 2 diabetes …

Introduction Orally administered semaglutide is the first glucagon-like peptide 1 receptor
agonist (GLP-1 RA) for oral administration. As head-to-head trials assessing orally …

Introduction: More than two-thirds of patients with type 1 diabetes (T1D) are overweight (OW)
and/or obese (OB) in the USA and Western Europe, resulting in insulin resistance as in type …